Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q4 2019 · 10-K
Revenue$0.00$0.00derived— vs Q4 2018 Net Income-$21.50M-$21.50MN/M vs Q4 2018 EPS Diluted-$0.65-$0.65N/M vs Q4 2018 Operating Income-$21,909,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
Operating Cash Flowderived-$16,294,000N/M Free Cash Flowderived-$17,468,000N/M ended Dec 31, 2019 · filed Feb 24, 2020 · 55 d after period end